Full Text View
Tabular View
No Study Results Posted
Related Studies
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
This study is ongoing, but not recruiting participants.
Study NCT00875745   Information provided by Indiana University

First Received on April 2, 2009.   Last Updated on October 15, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia, Myeloid, Acute
Leukemia, Promyelocytic, Acute
Myelodysplastic Syndromes
Additional conditions recognized in this trial
Leukemia
Leukemia, Myeloid
Preleukemia
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Neoplasms
Neoplasms by Histologic Type
Precancerous Conditions
Interventions listed in this trial
Sorafenib-Vorinostat
Additional drug interventions recognized in this trial
Sorafenib
Vorinostat
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Histone Deacetylase Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Indiana University School of Medicine
Bayer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services